Vertex Pharmaceuticals Announces Completion of Common Stock Offering
20 September 2006 - 11:15PM
PR Newswire (US)
CAMBRIDGE, Mass., Sept. 20 /PRNewswire-FirstCall/ -- Vertex
Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the
completion of its public offering of 9,100,000 shares of common
stock. The gross proceeds, before commissions and expenses, of the
public offering are $300.3 million. Merrill Lynch, Pierce, Fenner
& Smith Incorporated acted as the sole book-runner, Morgan
Stanley & Co. Incorporated acted as joint lead manager and UBS
Securities LLC acted as co-manager in this offering. This press
release does not constitute an offer to sell or the solicitation of
an offer to buy nor shall there be any sale of these securities in
any state in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state. A shelf registration statement
relating to the shares of common stock has been filed with the
Securities and Exchange Commission. This offering was made only by
means of a prospectus, including a prospectus supplement, forming a
part of this registration statement. A copy of the prospectus can
be obtained from Merrill Lynch's prospectus department, at 4 World
Financial Center, New York, NY 10080, 212-449-1000. About Vertex
Vertex Pharmaceuticals Incorporated is a global biotechnology
company committed to the discovery and development of breakthrough
small molecule drugs for serious diseases. The Company's strategy
is to commercialize its products both independently and in
collaboration with major pharmaceutical companies. Vertex's product
pipeline is focused on viral diseases, inflammation, autoimmune
diseases, cancer, pain and bacterial infection. Vertex
co-discovered the HIV protease inhibitor, Lexiva, with
GlaxoSmithKline. Lexiva is a registered trademark of the
GlaxoSmithKline group of companies. Vertex's press releases are
available at http://www.vrtx.com/ Vertex Contacts: Lynne H. Brum,
VP, Strategic Communications, (617) 444-6614 Michael Partridge,
Director, Corporate Communications, (617) 444-6108 Lora Pike,
Manager, Investor Relations, (617) 444-6755 DATASOURCE: Vertex
Pharmaceuticals Incorporated CONTACT: Lynne H. Brum, VP, Strategic
Communications, +1-617-444-6614, or Michael Partridge, Director,
Corporate Communications, +1-617-444-6108, or Lora Pike, Manager,
Investor Relations, +1-617-444-6755, all of Vertex Pharmaceuticals
Web site: http://www.vrtx.com/ Company News On-Call:
http://www.prnewswire.com/comp/938395.html
Copyright